Financial Performance - The company expects a net loss of 53 million yuan for the fiscal year 2024, a decline of 381.16% compared to the previous year's profit of 18.85 million yuan [3]. - The net loss after deducting non-recurring gains and losses is projected to be 56 million yuan, representing a decrease of 1,166.50% from the previous year's profit of 5.25 million yuan [3]. - The significant decline in performance is attributed to a decrease in the price of the core product, Sodium Acetate Ringer's Injection, due to policy impacts [5]. Cost Factors - Increased costs related to the clinical trials of the new traditional Chinese medicine, Yiphuijisheng Granules, have contributed to the financial downturn [6]. - The integration of Sichuan Duori Pharmaceutical Co., Ltd. has led to higher fixed asset depreciation and financial expenses [6]. Future Plans - The company plans to accelerate the R&D, production, and commercialization of intermediates and high-end peptide raw materials to create new revenue growth points [6]. Financial Reporting - The financial data presented is preliminary and has not been audited, with final figures to be disclosed in the 2024 annual report [7].
多瑞医药(301075) - 2024 Q4 - 年度业绩预告